<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131805</url>
  </required_header>
  <id_info>
    <org_study_id>14-001</org_study_id>
    <nct_id>NCT02131805</nct_id>
  </id_info>
  <brief_title>Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma</brief_title>
  <official_title>A Multicenter Pilot Study of Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lynn Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of electronic skin surface&#xD;
      brachytherapy (ESSB) for early stage basal or squamous cell carcinoma of the skin using a new&#xD;
      device. This new device is Nucletron's Esteya Electronic Skin Surface Brachytherapy System.&#xD;
      The investigators want to understand what effects, good and/or bad this device for delivering&#xD;
      brachytherapy has on your skin cancer. The investigators also want to assess the safety,&#xD;
      cosmetic results, the effects that ESSB has on quality of life and to correlate skin imaging&#xD;
      with clinical response to ESSB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of Electronic Skin Surface Brachytherapy (ESSB)</measure>
    <time_frame>3 years</time_frame>
    <description>Efficacy will be measured by local control of the irradiated BCC/SCC three years after brachytherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assess the cosmetic outcome of ESSB</measure>
    <time_frame>3 years</time_frame>
    <description>Cosmetic outcome will be patient-reported and clinician-assessed after brachytherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>(grade 1-4 adverse events). The study will use the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 for assessing toxicity related to brachytherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reported quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Patient reported health-related quality of life outcomes will be assessed using the Skindex-16 (Appendix A) and the Skin Cancer Index (Appendix B).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cutaneous Basal Cell</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Electronic Skin Surface Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Electronic Skin Surface Brachytherapy</intervention_name>
    <arm_group_label>Electronic Skin Surface Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of life assessment</intervention_name>
    <arm_group_label>Electronic Skin Surface Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 60 years old with estimated life expectancy of ≥ 5 years&#xD;
&#xD;
          -  Histopathologic diagnosis of basal or squamous cell carcinoma&#xD;
&#xD;
          -  Clinical stage T1N0M0 (by AJCC 2010 criteria)&#xD;
&#xD;
             °Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or&#xD;
             micronodular features must be ≤1 cm&#xD;
&#xD;
          -  Low risk pathologic features (by AJCC 2010 criteria)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (Appendix C)&#xD;
&#xD;
          -  Able and willing to complete the Skindex16 and Skin Cancer Index (must be able to&#xD;
             speak English)&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BCC/SCC that was previously treated (ie, recurrent BCC/SCC)&#xD;
&#xD;
          -  BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy&#xD;
&#xD;
          -  BCC/SCC on irregular surface (ie, target area not flat)&#xD;
&#xD;
          -  BCC/SCC adjacent to or overlapping with burn or scar&#xD;
&#xD;
          -  BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the&#xD;
             tibia, dorsum of hands and elbow)&#xD;
&#xD;
          -  BCC/SCC in area with compromised lymphatic drainage or vascular supply&#xD;
&#xD;
          -  BCC/SCC within 3 cm of another treated or untreated BCC/SCC&#xD;
&#xD;
          -  Inflammatory process in target area&#xD;
&#xD;
          -  Collagen vascular disease (lupus, scleroderma, rheumatoid arthritis)&#xD;
&#xD;
          -  Diabetes that is poorly controlled&#xD;
&#xD;
          -  Genetic disorder predisposing patient to skin cancers or radiation sensitivity (basal&#xD;
             cell nevus syndrome, xeroderma pigmentosum, ataxia telangiectasia mutans)&#xD;
&#xD;
          -  Receipt of treatment with another investigational device or drug&#xD;
&#xD;
          -  Receipt of drug that will affect biologic response to radiation (radiosensitizer or&#xD;
             radioprotector)&#xD;
&#xD;
          -  High likelihood of protocol non-compliance (in opinion of investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Consent only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent only)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent only)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>14-001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

